Patient engagement in healthcare: a preliminary set of measures to evaluate patient engagement in the European Reference Networks

Diana Marinello , Ilaria Galetti , Dorica Dan , Ammi Sundqvist Andersson , Silvia Aguilera , Simone Louisse , Lenja Wiehe , Anne-Laure Aslanian , Ines Hernando Martin

Rare Disease and Orphan Drugs Journal ›› 2022, Vol. 1 ›› Issue (1) : 2

PDF
Rare Disease and Orphan Drugs Journal ›› 2022, Vol. 1 ›› Issue (1) :2 DOI: 10.20517/rdodj.2021.001
Original Article

Patient engagement in healthcare: a preliminary set of measures to evaluate patient engagement in the European Reference Networks

Author information +
History +
PDF

Abstract

Aim: The European Reference Networks (ERNs) provide clinicians and patients the opportunity to collaborate at EU level to improve diagnosis, care and treatment for people living with rare and complex conditions. However, building a partnership culture to systematically involve patients in ERN activities and decision-making structures is challenging, partly because the role of patient representatives and the value of this collaboration are not always understood. The objective of this project was to develop an evaluation framework to assess the impact of patient engagement in the ERNs and to provide evidence on the value of patient-clinician partnership.

Methods: The evaluation was developed by EURORDIS and patient representatives involved in the ERNs (ePAG advocates) through a participatory and iterative process. The work was organised in three different phases: (1) clarify roles and identify common goals for ePAG advocates’ engagement in the ERNs; (2) define a set of measures; and (3) test the measures in three different ePAGs (European Patient Advocacy Groups).

Results: The project allowed developing a common understanding among ePAG advocates of their role and goals in the ERNs and defining a patient-driven evaluation framework to assess their level of engagement in the ERNs’ activities and how effectively they were working to fulfil their role.

Conclusion: Engaging with ERN clinicians to refine the framework would probably render it more relevant to the reality and priorities of the specific ERNs and more valuable as a tool to build a strong partnership culture. Such an evaluation framework could be integrated into the ERNs’ quality improvement system to ensure that the networks’ activities are driven by and remain responsive to patients’ needs.

Keywords

Patient engagement / evaluation / European Reference Networks / rare diseases / healthcare / monitoring / impact

Cite this article

Download citation ▾
Diana Marinello, Ilaria Galetti, Dorica Dan, Ammi Sundqvist Andersson, Silvia Aguilera, Simone Louisse, Lenja Wiehe, Anne-Laure Aslanian, Ines Hernando Martin. Patient engagement in healthcare: a preliminary set of measures to evaluate patient engagement in the European Reference Networks. Rare Disease and Orphan Drugs Journal, 2022, 1(1): 2 DOI:10.20517/rdodj.2021.001

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Le Cam Y, Bolz-johnson M. Expert by experience: valuing patient engagement in healthcare. In: Pomey M, Denis J, Dumez V, editors. Patient engagement. Cham: Springer International Publishing; 2019. p. 233-67.

[2]

Public Health. Available from: https://ec.europa.eu/health/ern/networks_en. [Last accessed on 23 Aug 2021]

[3]

Harrington RL,Oehrlein EM.Defining patient engagement in research: results of a systematic review and analysis: report of the ISPOR patient-centered special interest group.Value Heal2020;23:677-88

[4]

Bolz-Johnson M,Hoogerbrugge N.“Patient Journeys”: improving care by patient involvement.Eur J Hum Genet2020;28:141-3 PMCID:PMC6974600

[5]

Rosaria T,Valentina L.RarERN Path: a methodology towards the optimisation of patients’ care pathways in rare and complex diseases developed within the European Reference Networks.Orphanet J Rare Dis2020;15:347 PMCID:PMC7734838

[6]

Smith M,Marcinkute R.Telemedicine strategy of the European Reference Network ITHACA for the diagnosis and management of patients with rare developmental disorders.Orphanet J Rare Dis2020;15:103 PMCID:PMC7183125

[7]

EURORDIS - The Voice of Rare Disease Patients in Europe. Available from: https://www.eurordis.org/. [Last accessed on 23 Aug 2021]

[8]

Abelson J,Syrowatka A,Judd M.Evaluating patient, family and public engagement in health services improvement and system redesign.Healthc Q2018;21:61-7

[9]

Impact framework. Available from: https://www.england.nhs.uk/sustainableimprovement/impact-framework/. [Last accessed on 23 Aug 2021]

[10]

van Mierlo B. Regeer B van Amstel M et al Reflexive monitoring in action. A guide for monitoring system innovation projects. 2010. Available from: https://library.wur.nl/WebQuery/wurpubs/reports/395732. [Last accessed on 23 Aug 2021]

[11]

Vat LE,Robinson P.Evaluation of patient engagement in medicine development: A multi-stakeholder framework with metrics.Heal Expect2021;24:419-506 PMCID:PMC8077089

[12]

Boivin A,Gauvin FP.Patient and public engagement in research and health system decision making: A systematic review of evaluation tools.Heal Expect2018;21:1075-84 PMCID:PMC6250878

AI Summary AI Mindmap
PDF

127

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/